NCT03664024: Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)
- State
- Completed
- Phase
- Phase 2
- People
- 118 taking part
- Started
- 30 Oct 2018
- Primary completion
- 5 Nov 2021
- Arms
- Pembrolizumab Standard of Care
- Results
- Posted on the registry
- 10 Sep 2018: Trial registered
- 30 Oct 2018: Trial started
- 5 Nov 2021: Trial completed
- 14 Nov 2022: Trial results posted